Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in RAS-mutant Advanced Colorectal Cancer
NCT02619435Phase 2Unknown
- Sponsor
- National Cancer Institute
- Start
- Nov 2015
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in colorectal cancer (CRC), sponsored by National Cancer Institute. Status: unknown.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02619435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02619435.